Researchers at iStopMM have for the first time described the prevalence of smoldering multiple myeloma and the findings indicate that it is present in 0.5% of people over 40. The high prevalence of smoldering multiple myeloma has implications for future treatment policies in multiple myeloma because people with this precursor condition, in cases where it has a high chance of developing into malignant multiple myeloma, will probably be invited to start drug treatment in the next few years. The results of the study were recently published in Nature Medicine. See further.
iStopMM team member receives IMS Young Investigator Award
August 27, 2022
We are proud to announce that a PhD student at the University of Iceland and a member of the iStopMM team Jón Þórir Óskarsson was
